文献速递消化道出血消化内镜

止血喷雾粉TC-325治疗消化道出血:全国性研究及竞争风险分析

Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis.
PubMed 文献 · Gastrointest Endosc · 2019-06-17

该回顾性研究纳入西班牙21个中心的261例接受TC-325治疗的患者,其中83.9%为上消化道出血,73.2%作为挽救治疗。术中止血率为93.5%,术后30天失败率为27.4%,喷血、使用血管活性药物和低血压为失败的独立预测因素,30天总生存率为81.9%。

要点

  • TC-325术中止血率达93.5%,无论出血病因或部位,作为挽救治疗亦有效。
  • 术后30天失败率为27.4%,喷血、使用血管活性药物及低血压为独立预测因素。
  • 30天总生存率为81.9%,术中止血与更好预后相关(校正HR 0.29)。

核心结论

  • TC-325在超过90%的患者中实现术中止血,安全有效,无论出血病因或部位,包括作为挽救治疗。
  • 在该高风险队列中,30天失败率超过25%,喷血或血流动力学不稳定时失败率最高。

研究设计与样本

  • 回顾性研究,在西班牙21个中心进行,纳入截至2018年9月所有接受TC-325治疗的患者,共261例。

主要发现

  • 261例患者中219例(83.9%)为上消化道出血,最常见病因为消化性溃疡(28%)、恶性肿瘤(18.4%)和治疗性内镜相关出血(17.6%)。
  • TC-325作为挽救治疗用于191例(73.2%)患者。
  • 术中止血率为93.5%(95%CI 90%-96%)。
  • 术后第3、7、30天TC-325失败风险分别为21.1%、24.6%、27.4%。
  • 多因素分析显示喷血(P=0.004)、使用血管活性药物(P=0.02)和低血压(P=0.008)为失败的独立预测因素。

关键数值与推荐

  • 术中止血率93.5%(95%CI 90%-96%)。
  • 术后第3、7、30天失败风险分别为21.1%、24.6%、27.4%。
  • 30天总生存率81.9%(95%CI 76%-86%)。
  • 喷血P=0.004、使用血管活性药物P=0.02、低血压P=0.008为失败独立预测因素。
  • 术中止血与更好预后的校正HR 0.29(P=0.006)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: TC-325 (Hemospray, Cook Medical, Winston-Salem, NC) is an inorganic hemostatic powder recently approved by the U.S. Food and Drug Administration. This study aimed to examine the effectiveness, safety, and predictors of TC-325 failure in a large real-life cohort. METHODS: This was a retrospective study conducted at 21 Spanish centers. All patients treated with TC-325 until September 2018 were included. The primary outcome was treatment failure, defined as failed intraprocedural hemostasis or recurrent bleeding within the first 30 postprocedural days. Secondary outcomes included safety and survival. Risk and predictors of failure were assessed via competing-risk models. RESULTS: The cohort comprised 261 patients, of whom 219 (83.9%) presented with upper gastrointestinal bleeding (GIB). The most common causes were peptic ulcer (28%), malignancy (18.4%), and therapeutic endoscopy-related GIB (17.6%). TC-325 was used as rescue therapy in 191 (73.2%) patients. The rate of intraprocedural hemostasis was 93.5% (95% confidence interval [CI], 90%-96%). Risks of TC-325 failure at postprocedural days 3, 7, and 30 were 21.1%, 24.6%, and 27.4%, respectively. On multivariate analysis, spurting bleeding (P = .004), use of vasoactive drugs (P = .02), and hypotension (P = .008) were independent predictors of failure. Overall 30-day survival was 81.9% (95% CI, 76%-86%) and intraprocedural hemostasis was associated with a better prognosis (adjusted hazard ratio, 0.29; P = .006). Two severe adverse events were noted. CONCLUSION: TC-325 was safe and effective for intraprocedural hemostasis in more than 90% of patients, regardless of the cause or site of bleeding and its use as rescue therapy. In this high-risk cohort treated with TC-325, the 30-day failure rate exceeded 25% and was highest with spurting bleeding or hemodynamic instability.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Rodríguez de Santiago E, Burgos-Santamaría D, Pérez-Carazo L, et al. Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis. Gastrointest Endosc. 2019. PMID: 31220444. doi:10.1016/j.gie.2019.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。